Biotechnology and pharmaceutical companies operate in one of the most complex strategic environments in modern business. Success depends on far more than scientific discovery. Companies must make high-stakes decisions involving research portfolios, clinical development, regulatory strategy, intellectual property, manufacturing, market access, reimbursement, pricing, partnerships, acquisitions, commercialization, capital allocation, and global expansion—often before the ultimate value of a product is known.
Biotech & Pharma Strategy is an advanced Junior MBA course designed to develop practical managerial judgment for operating in life-sciences businesses. It moves beyond introductory discussions of drug development and healthcare markets to examine how executives make portfolio, financing, commercialization, and corporate-strategy decisions under extraordinary uncertainty.
Students will examine the full strategic lifecycle of a biotechnology or pharmaceutical asset—from scientific opportunity and target selection through development, regulatory approval, launch, lifecycle management, and eventual loss of exclusivity. Particular attention is given to the economics of probability, time, capital intensity, and portfolio risk. A promising therapy may require years of development, substantial investment, and multiple clinical and regulatory milestones before generating revenue. Executives must therefore decide not only whether a product could work, but also whether it should be developed, by whom, for which patients, against which competitors, with what evidence, under what financing model, and with what expected commercial value.
The course also examines the strategic differences between emerging biotechnology companies and large pharmaceutical firms. Students will explore licensing, co-development, strategic alliances, mergers and acquisitions, platform technologies, venture financing, manufacturing strategy, payer access, pricing, global commercialization, and portfolio renewal.
The central objective is to train students to think like life-sciences executives who must continuously balance scientific promise, patient benefit, regulatory feasibility, commercial attractiveness, capital requirements, development risk, competitive timing, and long-term enterprise value.
Course Objectives
By the end of this course, students will be able to:
• Analyze biotechnology and pharmaceutical companies as integrated scientific, financial, regulatory, and commercial enterprises.
• Evaluate drug-development opportunities using strategic and commercial criteria.
• Understand how uncertainty and probability influence life-sciences portfolio decisions.
• Assess research and development portfolios across different stages of maturity.
• Evaluate clinical development strategy from a managerial perspective.
• Understand how regulatory strategy influences development timing and commercial opportunity.
• Analyze intellectual-property strategy and exclusivity as sources of enterprise value.
• Evaluate licensing, co-development, alliance, and acquisition opportunities.
• Understand biotechnology venture financing and pharmaceutical capital allocation.
• Assess pharmaceutical commercialization and launch readiness.
• Evaluate payer, reimbursement, market-access, and pricing considerations.
• Understand manufacturing and supply-chain requirements for pharmaceuticals and biologics.
• Analyze competitive landscapes within therapeutic areas.
• Evaluate lifecycle-management strategies before and after product launch.
• Assess global market-entry and localization decisions in life sciences.
• Understand the strategic implications of generic and biosimilar competition.
• Evaluate platform technologies and pipeline optionality.
• Integrate scientific, regulatory, financial, and commercial information into investment decisions.
• Develop executive judgment regarding when to continue, partner, reprioritize, or terminate development programs.
• Apply portfolio thinking to long-term biotech and pharmaceutical strategy.
